The Impact of Initial Tumor Response on Survival Outcomes of Patients With HER2-Positive Advanced Breast Cancer Treated With Docetaxel, Trastuzumab, and Pertuzumab: An Exploratory Analysis of the CLEOPATRA Trial
-
Published:2024-07
Issue:5
Volume:24
Page:421-430.e3
-
ISSN:1526-8209
-
Container-title:Clinical Breast Cancer
-
language:en
-
Short-container-title:Clinical Breast Cancer
Author:
Debien VeroniqueORCID,
Agostinetto Elisa,
Bruzzone Marco,
Ceppi Marcello,
Martins-Branco Diogo,
Molinelli Chiara,
Jacobs Flavia,
Nader-Marta Guilherme,
Lambertini Matteo,
de Azambuja Evandro
Reference31 articles.
1. Current and future burden of breast cancer: global statistics for 2020 and 2040;Arnold;The Breast,2022
2. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016;Deluche;Eur J Cancer,2020
3. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer;Baselga;N Engl J Med,2012
4. Change in survival in metastatic breast cancer with treatment advances: meta-analysis and systematic review;Caswell-Jin;JNCI Cancer Spectrum,2018
5. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study;Swain;Lancet Oncol,2020